1084953-47-8

Basic information

• Product Name: 3-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-5-trifluoroMethyl-pyridine
• Synonyms: 3-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-5-trifluoroMethyl-pyridine
• CAS NO: 1084953-47-8
• Molecular Formula: C12H15BF3NO2
• Molecular Weight: 273.0592096
• Mol File: 1084953-47-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 357.889 °C at 760 mmHg
• Flash Point: 170.246 °C
• Appearance: /
• Density: 1.227 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-5-trifluoroMethyl-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-5-trifluoroMethyl-pyridine(1084953-47-8)
• EPA Substance Registry System: 3-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-5-trifluoroMethyl-pyridine(1084953-47-8)

Safety Data

• Hazardous Substances Data: 1084953-47-8(Hazardous Substances Data)

Usage

General Description

The chemical "3-(4,4,5,5-TetraMethyl-[1,3,2]dioxaborolan-2-yl)-5-trifluoroMethyl-pyridine" is a complex heterocyclic compound that contains a pyridine ring and a boron-containing group. The pyridine ring is substituted with a trifluoromethyl group at the 5-position, and the boron-containing group is attached at the 3-position. This chemical is a highly specialized compound often used in the field of organic synthesis and materials science. Its unique structure and properties make it useful for various applications, including as a building block for the synthesis of pharmaceuticals, agrochemicals, and advanced materials. Additionally, the boron-containing moiety in this compound can participate in certain reactions such as cross-coupling and Suzuki-Miyaura reactions, making it valuable in the field of organic chemistry.

Upstream product

• 3796-23-4 3-(trifluoromethyl)pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 123-91-1 1,4-dioxane 
• 436799-33-6 3-bromo-5-(trifluoromethyl)pyridine 

Downstream Products

• 1416000-28-6 10-(3-(trifluoromethyl)phenyl)-2-(5-(trifluoromethyl)pyridin-3-yl)pyrido[3,2-c][1,5]naphthyridin-9(10H)-one 

Relevant articles and documents

Enzyme-like Supramolecular Iridium Catalysis Enabling C?H Bond Borylation of Pyridines with meta-Selectivity

The use of secondary interactions between substrates and catalysts is a promising strategy to discover selective transition metal catalysts for atom-economy C?H bond functionalization. The most powerful catalysts are found via trial-and-error screening due to the low association constants between the substrate and the catalyst in which small stereo-electronic modifications within them can lead to very different reactivities. To circumvent these limitations and to increase the level of reactivity prediction in these important reactions, we report herein a supramolecular catalyst harnessing Zn???N interactions that binds to pyridine-like substrates as tight as it can be found in some enzymes. The distance and spatial geometry between the active site and the substrate binding site is ideal to target unprecedented meta-selective iridium-catalyzed C?H bond borylations with enzymatic Michaelis–Menten kinetics, besides unique substrate selectivity and dormant reactivity patterns.

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.